




RealRate

PHARMACEUTICAL 2020

Traverse Therapeutics Inc.
Rank 212 of 358





RealRate

PHARMACEUTICAL 2020

Traverse Therapeutics Inc. Rank 212 of 358



The relative strengths and weaknesses of Traverse Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Traverse Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 38% points. The greatest weakness of Traverse Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 106% points.

The company's Economic Capital Ratio, given in the ranking table, is 48%, being 11% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	429,064
Cost of Goods Sold	5,234
Intangible Assets	158,136
Liabilities, Current	95,449
Liabilities, Non-Current	20,894
Other Assets	14,709
Other Compr. Net Income	2,255
Other Expenses	37,530
Other Liabilities	267,261
Other Net Income	-9,087
Other Revenues	175,338
Property and Equipment	2,891
Research and Development	140,963
Selling, General and Administrative Expense	128,951

Output Variable	Value in 1000 USD
Assets	604,800
Liabilities	383,604
Expenses	312,678
Revenues	175,338
Stockholders Equity	221,196
Net Income	-146,427
Comprehensive Net Income	-145,300
Economic Capital Ratio	48%